Please ensure Javascript is enabled for purposes of website accessibility

Why bluebird bio, Inc. Stock Gained 10% in September

By Cory Renauer - Updated Oct 3, 2017 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another licensing deal with an important partner bodes well for the clinical-stage biotech.

What happened

Shares of bluebird bio, Inc. (BLUE 3.38%), a clinical-stage biotech developing cell-based therapies, rose 10% in September according to data from S&P Global Market Intelligence. Although there were a few positive developments last month, investors were mostly pleased with Celgene's (CELG) decision to license the second program from bluebird's growing stable of experimental cancer therapies.

So what 

At the end of September, Bluebird announced that it had dosed the first multiple myeloma patient in a phase 1 study with bb21217. This is the company's second in an exciting new class of treatments known as CAR-T that involves reprogramming a patient's own immune cells to recognize and fight cancer.

Rolled up dollar bills arranged in shape of an upward sloping chart.

Image source: Getty Images.

Bluebird stock soared in August when Gilead Sciences acquired a peer developing similar treatments for $11.9 billion, and the first CAR-T therapy, Kymriah from Novartis, earned an FDA approval. Although beginning clinical trials for a CAR-T candidate isn't necessarily a big deal on its own, the fact that bluebird's partner, Celgene, has already licensed the program speaks volumes about its odds of success down the road.

Now what

Celgene provided just $15 million upfront, and Bluebird is still on the hook for phase 1 trial expenses. If successful, though, Celgene will take over financial responsibility for further development and commercialization of bb21217, if it eventually earns an approval. Although the deal shifts a great deal of risk to Celgene, Bluebird remains entitled to pre-specified milestone payments and an unspecified royalty percentage on any sales.

The candidate's predecessor, bb2121, reduced disease activity in 15 of 15 evaluable patients in its phase 1 trial. It's hard to see how the new candidate can improve on such stellar data, but having a backup candidate to mitigate any unforeseen issues should help investors rest a bit easier.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$4.28 (3.38%) $0.14
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.36 (0.89%) $0.55
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Novartis AG Stock Quote
Novartis AG
NVS
$84.36 (-0.20%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.